01 / Contract Profile
75A50119C00037 Federal Contract Award
Agency code 7505
VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATES SERVICES FOR UP TO 10 YEARS.
02 / Contract Size and Status
What is the recorded size and timing of this contract?
03 / Spending Trend
75A50119C00037 contract spending by fiscal year
Annual net obligations across the complete period available for this agency and PIID, from the first recorded fiscal year through the latest contract action.
Latest fiscal year obligations$53.73M
FY 2026Net obligationsComplete recorded range
| Fiscal year | Net obligations | Actions | Change |
|---|---|---|---|
| FY 2019 | $23.67M | 1 | — |
| FY 2020 | $54.64M | 2 | +130.9% |
| FY 2021 | $56.55M | 3 | +3.5% |
| FY 2022 | $58.53M | 2 | +3.5% |
| FY 2023 | $60.58M | 2 | +3.5% |
| FY 2024 | $62.70M | 2 | +3.5% |
| FY 2025 | $51.92M | 5 | −17.2% |
| FY 2026 | $53.73M | 1 | +3.5% |
04 / Federal Buyer
Which organization manages this contract?
| Department | Contracting agency | Contracting office |
|---|---|---|
| HEALTH AND HUMAN SERVICES, DEPARTMENT OF | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE | ASPR/ORM-SNS |
05 / Contractor
Who holds this federal contract?
EMERGENT BIOSOLUTIONS CANADA INC
UEI XM23STFMVML6 · CAGE L0EM2
06 / NAICS Industries
Which industries classify this contract?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 325412 | PHARMACEUTICAL PREPARATION MANUFACTURING | $422.32M | 18 | 100.0% |
07 / Products and Services
What products or services were purchased?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 6505 | DRUGS AND BIOLOGICALS | $422.32M | 18 | 100.0% |
08 / Place of Performance
Where is the work recorded?
CANADA
ZIP R3T 5Y3
09 / Contract Actions
What modifications and obligations were recorded?
| Signed date | Modification | Obligation | Contracting office | NAICS | PSC |
|---|---|---|---|---|---|
| Mar 23, 2026 | P00017 | $53.73M | ASPR/ORM-SNSOffice code 75A503 | 325412 | 6505 |
| Jul 2, 2025 | P00016 | $51.92M | ASPR/ORM-SNSOffice code 75A503 | 325412 | 6505 |
| Jun 30, 2025 | P00015 | $0 | ASPR/ORM-SNSOffice code 75A503 | 325412 | 6505 |
| Jun 13, 2025 | P00014 | $0 | ASPR/ORM-SNSOffice code 75A503 | 325412 | 6505 |
| Jun 2, 2025 | P00013 | $0 | ASPR/ORM-SNSOffice code 75A503 | 325412 | 6505 |
| Mar 4, 2025 | P00012 | $0 | ASPR/ORM-SNSOffice code 75A503 | 325412 | 6505 |
| Jun 10, 2024 | P00011 | $62.70M | ASPR/ORM-SNSOffice code 75A503 | 325412 | 6505 |
| Feb 22, 2024 | P00010 | $0 | ASPR/ORM-SNSOffice code 75A503 | 325412 | 6505 |
| May 19, 2023 | P00009 | $60.58M | ASPR/ORM-SNSOffice code 75A503 | 325412 | 6505 |
| Mar 20, 2023 | P00008 | $0 | ASPR/ORM-SNSOffice code 75A503 | 325412 | 6505 |
| Apr 5, 2022 | P00007 | $58.53M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 325412 | 6505 |
| Mar 29, 2022 | P00006 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 325412 | 6505 |
| Oct 25, 2021 | P00005 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 325412 | 6505 |
| May 26, 2021 | P00004 | $56.55M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 325412 | 6505 |
| Mar 26, 2021 | P00003 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 325412 | 6505 |
10 / Reading the Contract
How should this award record be interpreted?
Read the PIID as a transaction history, not as a single purchase price. Net obligations combine the base action with later increases, reductions, corrections, and deobligations recorded under the same contract.
Verify the buyer
Agency and office identify who manages the procurement relationship.
Follow modifications
Each action can change funding, scope, dates, or administrative terms.
Compare the market
Use NAICS, PSC, and the contractor profile to identify related buyers and competitors.